A proposal of an updated classification for pelvic relapses of rectal cancer to guide surgical decision-making.
classification
locally recurrent rectal cancer
resection margin
surgery
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
02
04
2020
accepted:
05
04
2020
pubmed:
20
5
2020
medline:
12
8
2020
entrez:
20
5
2020
Statut:
ppublish
Résumé
Selection of patients affected by pelvic recurrence of rectal cancer (PRRC) who are likely to achieve a R0 resection is mandatory. The aim of this study was to propose a classification for PRRC to predict both radical surgery and disease-free survival (DFS). PRRC patients treated at the National Cancer Institute of Milan (Italy) were included in the study. PRRC were classified as S1, if located centrally (S1a-S1b) or anteriorly (S1c) within the pelvis; S2, in case of sacral involvement below (S2a) or above (S2b) the second sacral vertebra; S3, in case of lateral pelvic involvement. Of 280 reviewed PRRC patients, 152 (54.3%) were evaluated for curative surgery. The strongest predictor of R+ resection was the S3 category (OR, 6.37; P = .011). Abdominosacral resection (P = .012), anterior exenteration (P = .012) and extended rectal re-excision (P = .003) were predictive of R0 resection. S3 category was highly predictive of poor DFS (HR 2.53; P = .038). DFS was significantly improved after R0 surgery for S1 (P < .0001) and S2 (P = .015) patients but not for S3 cases (P = .525). The proposed classification allows selection of subjects candidates to curative surgery, emphasizing that lateral pelvic involvement is the main predictor of R+ resection and independently affects the DFS.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Selection of patients affected by pelvic recurrence of rectal cancer (PRRC) who are likely to achieve a R0 resection is mandatory. The aim of this study was to propose a classification for PRRC to predict both radical surgery and disease-free survival (DFS).
METHODS
METHODS
PRRC patients treated at the National Cancer Institute of Milan (Italy) were included in the study. PRRC were classified as S1, if located centrally (S1a-S1b) or anteriorly (S1c) within the pelvis; S2, in case of sacral involvement below (S2a) or above (S2b) the second sacral vertebra; S3, in case of lateral pelvic involvement.
RESULTS
RESULTS
Of 280 reviewed PRRC patients, 152 (54.3%) were evaluated for curative surgery. The strongest predictor of R+ resection was the S3 category (OR, 6.37; P = .011). Abdominosacral resection (P = .012), anterior exenteration (P = .012) and extended rectal re-excision (P = .003) were predictive of R0 resection. S3 category was highly predictive of poor DFS (HR 2.53; P = .038). DFS was significantly improved after R0 surgery for S1 (P < .0001) and S2 (P = .015) patients but not for S3 cases (P = .525).
CONCLUSIONS
CONCLUSIONS
The proposed classification allows selection of subjects candidates to curative surgery, emphasizing that lateral pelvic involvement is the main predictor of R+ resection and independently affects the DFS.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
350-359Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Kapiteijn E, Marijnen CAM, Nagtegaal ID. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. New Engl J Med. 2001;345:638-646.
Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision and rectal cancer. Lancet. 1986;1:1479-1482.
Van den Brink M, Stiggelbout AM, Van den Hout WB, et al. Clinical nature and prognosis of locally recurrent rectal cancer after total mesorectal excision with or without preoperative radiotherapy. J Clin Oncol. 2004;22:3958-3964.
Hagemans JAW, van Rees JM, Alberda WJ, et al. Locally recurrent rectal cancer; long-term outcome of curative surgical and non-surgical treatment of 447 consecutive patients in a tertiary referral centre. Eur J Surg Oncol. 2020;46(3):448-458.
Westberg K, Palmer G, Hjern F, Johansson H, Holm T, Martling A. Management and prognosis of locally recurrent rectal cancer - A national population-based study. Eur J Surg Oncol. 2018;44(1):100-107.
PelvEx Collaborative. Factors affecting outcomes following pelvic exenteration for locally recurrent rectal cancer. Br J Surg. 2018;105(6):650-657.
Rausa E, Kelly ME, Bonavina L, O'Connell PR, Winter DC. A systematic review examining quality of life following pelvic exenteration for locally advanced and recurrent rectal cancer. Colorectal Dis. 2017;19(5):430-436.
Pellino G, Sciaudone G, Candilio G, Selvaggi F. Effect of surgery on health-related quality of life of patients with locally recurrent rectal cancer. Dis Colon Rectum. 2015;58(8):753-761.
Westberg K, Palmer G, Hjern F, Holm T, Martling A. Population-based study of surgical treatment with and without tumour resection in patients with locally recurrent rectal cancer. Br J Surg. 2019;106(6):790-798.
Suzuki K, Devine RM, Dozois RR, et al. Intraoperative irradiation after palliative surgery for locally recurrent rectal cancer. Cancer. 1995;75:939-952.
Pilipshen SJ, Heilweil M, Quan SH, Sternberg SS, Enker WE. Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer. 1984;53:1354-1362.
Guillem JG, Ruo L. Strategies in operative therapy for locally recurrent rectal cancer. Semin Colon Rectal Surg. 1998;9:259-268.
Wanebo HJ, Antoniuk P, Koness JR, et al. Pelvic resection of recurrent rectal cancer: technical considerations and outcomes. Dis Colon Rectum. 1999;42:1438-1448.
Yamada K, Ishizawa T, Niwa K, Chuman Y, Akiba S, Aikou T. Patterns of pelvic invasion are prognostic in the treatment of locally recurrent rectal cancer. Br J Surg. 2001;88:988-993.
Boyle KM, Sagar PM, Chalmers AG, Sebag-Montefiore D, Cairns A, Eardley I. Surgery for locally recurrent rectal cancer. Dis Colon Rectum. 2005;48:929-937.
Kusters M, Marijnen CAM, van de Velde CJH, et al. Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial. Eur J Surg Oncol. 2010;36:470-476.
Georgiou PA, Tekkis PP, Constantinides VA, et al. Diagnostic accuracy and value of magnetic resonance imaging (MRI) in planning exenterative pelvic surgery for advanced colorectal cancer. Eur J Cancer. 2013;49:72-81.
Troja A, El-Sourani N, Abdou A, Antolovic D, Raab HR. Surgical options for locally recurrent rectal cancer--review and update. Int J Colorectal Dis. 2015;30(9):1157-1163.
van der Meij W, Rombouts AJ, Rütten H, Bremers AJ, de Wilt JH. Treatment of Locally Recurrent Rectal Carcinoma in Previously (Chemo)Irradiated Patients: A Review. Dis Colon Rectum. 2016;59(2):148-156.
Moore HG, Shoup M, Riedel E, et al. Colorectal cancer pelvic recurrences: determinants of resectability. Dis Colon Rectum. 2004;47(10):1599-1606.
Milne T, Solomon MJ, Lee P, Young JM, Stalley P, Harrison JD. Assessing the impact of a sacral resection on morbidity and survival after extended radical surgery for locally recurrent rectal cancer. Ann Surg. 2013;258(6):1007-1013.
Lau YC, Jongerius K, Wakeman C, et al. Influence of the level of sacrectomy on survival in patients with locally advanced and recurrent rectal cancer. Br J Surg. 2019;106(4):484-490.
Shaikh I, Aston W, Hellawell G, et al. Extended lateral pelvic sidewall excision (ELSiE): an approach to optimize complete resection rates in locally advanced or recurrent anorectal cancer involving the pelvic sidewall. Tech Coloproctol. 2014;18:1161-1168.
Nielsen MB, Rasmussen P, Johnny K, Laurberg S. Preliminary experience with external hemipelvectomy for locally advanced and recurrent pelvic carcinoma. Colorectal Dis. 2012;14:152-156.
Belli F, Gronchi A, Corbellini C, Milione M, Leo E. Abdominosacral resection for locally recurring rectal cancer. World J Gastrointest Surg. 2016;8(12):770-778.
Tanaka H, Yamaguchi T, Hachiya K, et al. Radiotherapy for locally recurrent rectal cancer treated with surgery alone as the initial treatment. Radiat Oncol J. 2017;35(1):71-77.
Ito Y, Ohtsu A, Ishikura S, et al. Efficacy of chemoradiotherapy on pain relief in patients with intrapelvic recurrence of rectal cancer. Jpn J Clin Oncol. 2003;33(4):180-185.
Valentini V, Morganti AG, Gambacorta MA, et al. Study Group for Therapies of Rectal Malignancies (STORM). Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: a multicentric phase II study. Int J Radiat Oncol Biol Phys. 2006;64(4):1129-1139.
Yamada S, Kamada T, Ebner DK, et al. Working group on locally recurrent rectal cancer. Carbon-ion radiation therapy for pelvic recurrence of rectal cancer. Int J Radiat Oncol Biol Phys. 2016;96(1):93-101.
Shinoto M, Yamada S, Okamoto M, et al. Carbon-ion radiotherapy for locally recurrent rectal cancer: Japan Carbon-ion Radiation Oncology Study Group (J-CROS) study 1404 rectum. Radiother Oncol. 2019;132:236-240.